Question 1

What is Inovio Pharmaceuticals, Inc.'s WACC?

Accepted Answer

Inovio Pharmaceuticals, Inc. (INO) has a Weighted Average Cost of Capital (WACC) of 9.96%. This is calculated using a Cost of Equity of 9.96% (via CAPM with a beta of 1.52) and a pre-tax Cost of Debt of 5.00%, with an equity weight of 100.00% in the capital structure.

Question 2

Is Inovio Pharmaceuticals, Inc.'s WACC high or low?

Accepted Answer

Inovio Pharmaceuticals, Inc.'s WACC of 9.96% falls within the typical 8-12% range for mid-cap growth companies. WACC is used as the discount rate in DCF valuations — a lower WACC results in higher present values of future cash flows.

Question 3

How is Inovio Pharmaceuticals, Inc.'s WACC calculated?

Accepted Answer

Inovio Pharmaceuticals, Inc.'s WACC is calculated using the formula: WACC = (E/V × Re) + (D/V × Rd × (1-T)). The Cost of Equity (Re) of 9.96% is derived from the CAPM model using a beta of 1.52. The pre-tax Cost of Debt (Rd) is 5.00%. The capital structure is 100.00% equity and 0.00% debt.

Inovio Pharmaceuticals, Inc. (INO) — WACC 分析

WACC 构成

解读

Inovio Pharmaceuticals, Inc.（INO）WACC：9.96%

WACC计算器

Inovio Pharmaceuticals, Inc.（INO） WACC 解读

INO 公司分析

INO DCF 估值

继续做同行对比